Company: REVB
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0000950170-25-083815
Chunk: 40

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 40
---
 affirmative vote majority of the number of shares of stock entitled to vote thereon and present (either in person or by proxy).

<div align='center'>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL 5.

23

PROPOSAL 6: APPROVAL FOR THE ISSUANCE OF COMMON STOCK UNDERLYING WARRANTS IN EXCESS OF THE NASDAQ EXCHANGE CAP</div>

Our common stock is currently listed on Nasdaq and, as such, we are subject to Nasdaq rules, which require us to obtain stockholder approval prior to the issuance of our common stock in connection with certain non-public offerings involving the sale, issuance or potential issuance by the Company of common stock (or securities convertible into or exercisable for common stock) equal to 20% or more of the common stock outstanding before the issuance.

Overview

On May 29, 2025, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors, pursuant to which the Company is obliged to issue Class H Common Stock Warrants (the “Class H Common Stock Warrants”) in connection with a best-efforts offering (the “Offering.”) The Class H Common Stock Warrants will be exercisable beginning on the effective date of such stockholder approval (“Stockholder Approval”). Each Class H Common Stock Warrant is exercisable at an exercise price of $1.10 share and will expire five years from the initial exercise date.

The Company raised net proceeds of $3.4 million in connection with the SPA.

Reasons for Securities Purchase Agreement

We have funded our operations since our inception to March 31, 2025 through the issuance and sale of our capital stock, from which we have raised net proceeds of $56.8 million. Our current cash and cash equivalents balance will not be sufficient to complete all necessary product development or future commercialization efforts. We anticipate that our current cash and cash equivalents balance will not be sufficient to sustain operations within one-year after the date that our audited financial statements for March 31, 2025 were issued, which raises substantial doubt about our ability to continue as a going concern.

We plan to seek additional funding through public or private equity or debt financings. We may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our stockholders. If we are unable to obtain funding we could be required to delay, reduce or